Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Genital warts and cost of care in England.

Desai S, Wetten S, Woodhall SC, Peters L, Hughes G, Soldan K.

Sex Transm Infect. 2011 Oct;87(6):464-8. doi: 10.1136/sti.2010.048421. Epub 2011 Aug 3.

2.

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.

Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK.

Lancet Infect Dis. 2011 Jan;11(1):39-44. doi: 10.1016/S1473-3099(10)70225-5. Epub 2010 Nov 8.

PMID:
21067976
3.

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

FUTURE I/II Study Group., Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R.

BMJ. 2010 Jul 20;341:c3493. doi: 10.1136/bmj.c3493.

4.

Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England.

Howell-Jones R, Bailey A, Beddows S, Sargent A, de Silva N, Wilson G, Anton J, Nichols T, Soldan K, Kitchener H; Study Group Collaborators..

Br J Cancer. 2010 Jul 13;103(2):209-16. doi: 10.1038/sj.bjc.6605747. Erratum in: Br J Cancer. 2010 Sep 7;103(6):928.

5.

Long-term quality of life effects of genital warts - a follow-study.

Mortensen GL.

Dan Med Bull. 2010 Apr;57(4):A4140.

PMID:
20385081
6.

Genital warts incidence and healthcare resource utilisation in Australia.

Pirotta M, Stein AN, Conway EL, Harrison C, Britt H, Garland S.

Sex Transm Infect. 2010 Jun;86(3):181-6. doi: 10.1136/sti.2009.040188. Epub 2009 Dec 3.

7.

Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom.

Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ.

Vaccine. 2010 May 28;28(24):4091-102. doi: 10.1016/j.vaccine.2009.09.125. Epub 2009 Nov 10.

PMID:
19909831
8.

Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.

Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS.

Sex Transm Infect. 2009 Dec;85(7):499-502. doi: 10.1136/sti.2009.037788. Epub 2009 Oct 16.

PMID:
19837728
9.

Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom.

Woodhall SC, Jit M, Cai C, Ramsey T, Zia S, Crouch S, Birks Y, Newton R, Edmunds WJ, Lacey CJ.

Sex Transm Dis. 2009 Aug;36(8):515-21. doi: 10.1097/OLQ.0b013e3181a74c2c.

PMID:
19543143
10.

Patients with genital warts have a decreased quality of life.

Marra C, Ogilvie G, Gastonguay L, Colley L, Taylor D, Marra F.

Sex Transm Dis. 2009 Apr;36(4):258-60. doi: 10.1097/OLQ.0b013e318191a55e. No abstract available.

PMID:
19265737
11.

(Not) warts and all. Government fully considered HPV vaccine.

Salisbury DM.

BMJ. 2008 Nov 19;337:a2552. doi: 10.1136/bmj.a2552. No abstract available.

PMID:
19019858
12.

Determining the cost of genital warts: a study from Ireland.

Dee A, Howell F, O'Connor C, Cremin S, Hunter K.

Sex Transm Infect. 2009 Sep;85(5):402-3. doi: 10.1136/sti.2008.033837. Epub 2008 Nov 12.

PMID:
19004863
13.

Epidemiology and costs associated with genital warts in Canada.

Marra F, Ogilvie G, Colley L, Kliewer E, Marra CA.

Sex Transm Infect. 2009 Apr;85(2):111-5. doi: 10.1136/sti.2008.030999. Epub 2008 Nov 3.

PMID:
18981170
14.

(Not) warts and all.

Hammond P.

BMJ. 2008 Oct 23;337:a2186. doi: 10.1136/bmj.a2186. No abstract available.

PMID:
18948345
15.

Government decision on national human papillomavirus vaccine programme is a sad day for sexual health.

O'Mahony C.

Sex Transm Infect. 2008 Aug;84(4):251. doi: 10.1136/sti.2008.032755. No abstract available.

PMID:
18647875
16.

Economic evaluation of human papillomavirus vaccination in the United Kingdom.

Jit M, Choi YH, Edmunds WJ.

BMJ. 2008 Jul 17;337:a769. doi: 10.1136/bmj.a769.

17.

Estimation of the impact of genital warts on health-related quality of life.

Woodhall S, Ramsey T, Cai C, Crouch S, Jit M, Birks Y, Edmunds WJ, Newton R, Lacey CJ.

Sex Transm Infect. 2008 Jun;84(3):161-6. doi: 10.1136/sti.2007.029512. Epub 2008 Mar 13. Erratum in: Sex Transm Infect. 2008 Aug;84(4):328.

PMID:
18339658
18.

[Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France].

Monsonégo J, Breugelmans JG, Bouée S, Lafuma A, Bénard S, Rémy V.

Gynecol Obstet Fertil. 2007 Feb;35(2):107-13. Epub 2007 Jan 30. French.

PMID:
17270482
19.

Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.

Brown RE, Breugelmans JG, Theodoratou D, Bénard S.

Curr Med Res Opin. 2006 Apr;22(4):663-70.

PMID:
16684427
20.

Development and duration of human papillomavirus lesions, after initial infection.

Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, Koutsky LA.

J Infect Dis. 2005 Mar 1;191(5):731-8. Epub 2005 Jan 21.

PMID:
15688287

Supplemental Content

Support Center